Login
Celcuity Inc. logo

Celcuity Inc.

celcuity.com

What Do They Do?

Develops gedatolisib, a targeted cancer drug being tested for advanced breast cancer and metastatic prostate cancer.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −67% (Loss)
vs −$43.8M in Q3 FY2025
  • Aug 26, 2026 Celcuity submits application for REVTORPYK in PIK3CA-mutant breast cancer
  • Jul 15, 2026 FDA approves REVTORPYK for PIK3CA wild-type advanced breast cancer

Prostate cancer program The earlier report described gedatolisib’s initial development program as focused on advanced breast cancer; the latest report also describes an ongoing study for metastatic prostate cancer.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support